Verrica Pharmaceuticals (VRCA) Change in Accured Expenses (2017 - 2026)

Verrica Pharmaceuticals' Change in Accured Expenses history runs 10 years deep, the most recent figure standing at -$586000.0 for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 160.23% year-over-year to -$586000.0; the TTM figure through Mar 2026 stood at -$2.9 million (down 122.65% YoY), while the FY2025 annual figure was -$1.3 million, down 345.92% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$586000.0, down from -$400000.0 in the prior quarter.
• The five-year high for Change in Accured Expenses was $5.5 million in Q3 2023, with the low at -$5.2 million in Q4 2024.
• The 5-year median for Change in Accured Expenses is $545000.0 (2022), against an average of $520294.1.
• The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses slumped 581.82% in 2022, then surged 7011.11% in 2023.
• Verrica Pharmaceuticals' Change in Accured Expenses stood at $72000.0 in 2022, then soared by 7011.11% to $5.1 million in 2023, then plunged by 201.17% to -$5.2 million in 2024, then surged by 92.28% to -$400000.0 in 2025, then sank by 46.5% to -$586000.0 in 2026.
• Business Quant data shows VRCA's Change in Accured Expenses at -$586000.0 in Q1 2026, -$400000.0 in Q4 2025, and -$501000.0 in Q3 2025.